Novel Cancer Stem Marker and Its Applicability for Grading Primary Human Gliomas

Technol Cancer Res Treat. 2018 Jan 1:17:1533034617753812. doi: 10.1177/1533034617753812.

Abstract

Poorly differentiated cell populations including tumor-initiating stem cells have been demonstrated to display a unique ability to natively internalize fragmented double-stranded DNA. Using this feature as a marker, we show that 0.1% to 6% of human glioblastoma cells from the bioptates can effectively internalize a fluorescently labeled DNA probe. Of these, using samples from 3 patients, 66% to 100% cells are also positive for CD133, a well-established surface marker of tumor-initiating glioma stem cells. Using the samples from primary malignant brain lesions (33 patients), we demonstrate that tumor grading significantly correlates ( R = .71) with the percentage of DNA-internalizing cells. No such correlation is observed for relapse samples (18 patients).

Keywords: CD133; TAMRA-DNA; glioblastoma; neurosphere; tumor-initiating stem cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • AC133 Antigen
  • Biomarkers, Tumor*
  • Brain Neoplasms / metabolism*
  • Brain Neoplasms / pathology*
  • Brain Neoplasms / surgery
  • DNA, Neoplasm / genetics
  • DNA, Neoplasm / metabolism
  • Fluorescent Antibody Technique
  • Glioma / genetics
  • Glioma / metabolism*
  • Glioma / pathology*
  • Glioma / surgery
  • Humans
  • Neoplasm Grading
  • Neoplastic Stem Cells / metabolism*
  • Neoplastic Stem Cells / pathology
  • Tumor Cells, Cultured

Substances

  • AC133 Antigen
  • Biomarkers, Tumor
  • DNA, Neoplasm